Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT02337452
Collaborator
National Cancer Institute (NCI) (NIH)
10,000
1
396.7
25.2

Study Details

Study Description

Brief Summary

This trial develops a patient-driven self-navigated web-based family outreach program for cancer prevention in high-risk families. Creating the family outreach program may help to improve the way in which genetic test results are communicated within families and increase the number of at-risk relatives who become aware of their risks.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaire Administration
  • Behavioral: Web Site

Detailed Description

PRIMARY OBJECTIVES:
  1. To develop a secure, web-based program for family outreach in Clinical Cancer Genetics (CCG).

  2. The long-term goals of this program are expected to include, but are not limited to the following:

IIa. To enable families with inherited cancer susceptibility and/or at increased familial risk of cancer to provide personal and family history of neoplasia through a convenient and self-directed program.

IIb. To enable communication of possible inherited cancer susceptibility with and among family members through the web-based portal.

IIc. To facilitate genetic testing, screening and prevention strategies in those at risk.

IId. Establish high-risk cohort for optional participation in research and clinical trials.

OUTLINE:

Patients communicate with at-risk family members to share genetic test results and other relevant information, as well as to learn more about their disease via family outreach program website. At risk family members are then contacted by a study coordinator or genetic counselor for further follow-up. At-risk relatives receive resources to facilitate understanding of their at-risk status and to facilitate predictive testing.

Study Design

Study Type:
Observational
Anticipated Enrollment :
10000 participants
Observational Model:
Family-Based
Time Perspective:
Prospective
Official Title:
The Patient-Driven Self-Navigated Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families
Actual Study Start Date :
Apr 10, 2015
Anticipated Primary Completion Date :
Apr 30, 2048
Anticipated Study Completion Date :
Apr 30, 2048

Arms and Interventions

Arm Intervention/Treatment
Observational (family outreach program)

Patients communicate with at-risk family members to share genetic test results and other relevant information, as well as to learn more about their disease via family outreach program website. At risk family members are then contacted by a study coordinator or genetic counselor for further follow up. At-risk relatives receive resources to facilitate understanding of their at-risk status and to facilitate predictive testing.

Other: Questionnaire Administration
Ancillary studies

Behavioral: Web Site
Communicate via family outreach program website
Other Names:
  • Internet Website
  • Website
  • www-website
  • Outcome Measures

    Primary Outcome Measures

    1. Web-Based Family Outreach Registry [Continual assessment of data over participant's life time (target follow-up duration: 40 Years)]

      Data analysis for core functions of the web-based Family Outreach Registry will generally be descriptive. Web-based program to improve the way in which genetic test results are communicated within families and to increase the number of at-risk relatives who become aware of their risks.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Individuals who have been diagnosed with a hereditary cancer-causing mutation. Individuals may be identified through clinical testing as patients at MD Anderson or patients whose mutation was identified at an outside institution who contact the registry

    • Individuals that have clinical suspicion for syndromic cancer susceptibility, but in whom mutational testing has been nondiagnostic (depending on condition in question, nondiagnostic testing may be as little as 10%, as in familial adenomatous polyposis [FAP], or as high as 70% in suspected hereditary diffuse gastric cancer or HDGC)

    • At-risk family members of individuals with a cancer causing mutation or of individuals with nondiagnostic testing notwithstanding presence of likely syndromic cancer. Such patients will in most cases not be MD Anderson patients. Note: The enrollment, consenting, and evaluation process anticipates and addresses this.

    Exclusion Criteria:
    • Index patients who test negative for a cancer causing mutation, except for those agreeing to provide family history (FH) that is informative for at-risk individuals when no other source of such information is available

    • Patients who are unwilling or are unable to provide informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 M D Anderson Cancer Center Houston Texas United States 77030

    Sponsors and Collaborators

    • M.D. Anderson Cancer Center
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Patrick M Lynch, M.D. Anderson Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    M.D. Anderson Cancer Center
    ClinicalTrials.gov Identifier:
    NCT02337452
    Other Study ID Numbers:
    • 2014-0715
    • NCI-2020-00567
    • 2014-0715
    • P30CA016672
    First Posted:
    Jan 13, 2015
    Last Update Posted:
    Feb 6, 2020
    Last Verified:
    Feb 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 6, 2020